INDIANAPOLIS, United States, May 26, 2026
Eli Lilly and Company has announced three major biotechnology acquisitions aimed at significantly expanding its infectious disease research and vaccine development portfolio. The pharmaceutical giant confirmed agreements to acquire Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc., strengthening Lilly’s long-term strategy to prevent infectious diseases linked to severe neurological, oncological, and antimicrobial resistance-related health risks. The deals represent one of Lilly’s largest recent expansions into infectious disease prevention and vaccine innovation, reinforcing growing industry focus on next-generation immunization technologies and global public health preparedness.
The acquisitions include vaccine platforms targeting shingles, Staphylococcus aureus infections, gonorrhea, chlamydia, and Epstein-Barr Virus (EBV), areas increasingly recognized for their connection to long-term diseases including dementia, cancer, infertility, and neurological disorders. Lilly executives stated that the strategy reflects a shift toward preventing disease at its source rather than only treating later-stage complications.
Lilly Strengthens Vaccine and Infectious Disease Pipeline
According to Lilly, the acquisitions are designed to accelerate development of differentiated vaccine technologies capable of addressing major unmet medical needs worldwide. The company emphasized that infectious diseases continue to create substantial global morbidity not only during acute infection but also through long-term downstream health consequences.
The largest transaction involves Vaccine Company, whose shareholders could receive up to $1.55 billion in cash through upfront and milestone-based payments. The company is developing proprietary In Vivo Nanoparticle (IVN) technology designed to generate durable immune responses without the complex manufacturing requirements associated with traditional virus-like particle vaccines. Its lead preclinical program targets Epstein-Barr Virus (EBV), a virus increasingly linked to multiple sclerosis and several malignancies.
Advertisement
Lilly also announced plans to acquire Curevo Inc. for up to $1.5 billion. Curevo’s lead candidate, amezosvatein, is an investigational shingles vaccine developed using a next-generation synthetic adjuvant platform. In Phase 2 studies, the vaccine reportedly matched immune response benchmarks of current standard-of-care shingles vaccines while significantly reducing common side effects such as fatigue, chills, and injection-site pain. Researchers believe broader adoption of better-tolerated shingles vaccines could help reduce long-term risks associated with shingles, including stroke and dementia.
LimmaTech Acquisition Targets Antimicrobial Resistance
The third acquisition focuses on LimmaTech Biologics AG, a Swiss biotechnology company developing vaccines targeting bacterial pathogens increasingly resistant to antibiotics. Lilly stated the transaction could reach $780 million, including milestone-based payments tied to future clinical and regulatory progress.
LimmaTech’s lead program, LTB-SA7, is currently in Phase 1 development as a vaccine targeting Staphylococcus aureus, a major cause of surgical-site infections worldwide. The company is also advancing programs focused on difficult-to-treat pathogens including Neisseria gonorrhoeae and Chlamydia trachomatis, infections associated with infertility and other severe long-term complications, particularly among women.
Industry experts continue warning that growing antimicrobial resistance threatens the effectiveness of many existing antibiotic therapies. Lilly executives noted that vaccines may become increasingly critical in reducing disease burden and preventing infections that are becoming progressively harder to treat using traditional antimicrobial drugs.
Major Investment Signals Expanding Vaccine Innovation Strategy
Lilly’s leadership described the acquisitions as part of a broader strategic initiative to build advanced prevention technologies capable of reducing long-term healthcare burdens associated with infectious diseases. Daniel M. Skovronsky, M.D., Ph.D., Lilly’s Chief Scientific and Product Officer and President of Lilly Research Laboratories, stated that emerging evidence increasingly links common infections to serious chronic diseases appearing years after initial infection.
The acquisitions also highlight rising pharmaceutical industry investment in vaccine innovation and preventive healthcare technologies. Analysts believe the global vaccine sector is entering a new growth phase fueled by advances in immunology, nanoparticle technologies, synthetic adjuvants, and precision vaccine design.
All three transactions remain subject to customary closing conditions and regulatory approvals. Once completed, the deals are expected to significantly strengthen Lilly’s research capabilities across infectious disease prevention, immunology, and vaccine commercialization.
Source: Eli Liily, Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc. press release
